Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
SSTR positive
i
Other names:
SSTR, Somatostatin Recepto
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related biomarkers:
Expression
‹
›
Associations
(7)
News
Trials
Search handles
Search handles
Filter by
Latest
1year
#AACR23 poster w/ Drs. @SusanneArnoldMD @AmanChauhanMD for #ETCTN (10388): First in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). https://t.co/79XJntQkIM (@NCICTEP_ClinRes)
1 year ago
SSTR (Somatostatin Receptor)
|
SSTR positive
|
Lutathera (lutetium Lu 177 dotatate) • Triapine (3-AP)
1year
The @AACR Annual Meeting is underway with some of our experts presenting the latest data on #NETs❗️18 Apr, Tue, @AmanChauhanMD | ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive GEP-NETs (@net_connectinfo)
1 year ago
P1 data
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
Lutathera (lutetium Lu 177 dotatate) • Triapine (3-AP)
over1year
Today at 1 pm CT .@thomashopemd @UCSFCancer .@SukiPaddaMD @CedarsSinai present an update on @ALLIANCE_org A021901 - a trial for pts w/somatostatin receptor-positive advanced bronchial neuroendocrine tumors. Join in or visit https://t.co/J1PTqHC2pz #AllianceFall22 #NCI #NCTN #NETs (@ALLIANCE_org)
over 1 year ago
Clinical
|
SSTR (Somatostatin Receptor)
|
SSTR positive
over2years
.@RadioMedix Awarded $2.0 M NCI SBIR Direct-to-Phase II Grant to Develop Drug for Targeted Alpha-Emitter Therapy for Somatostatin Receptor-Positive #NeuroendocrineTumors https://t.co/3AoirFv7ur @delpassand @iza_tworowska @theNCI #theranostics (@CarcinoidNETs)
over 2 years ago
SSTR (Somatostatin Receptor)
|
SSTR positive
over2years
Newly Activated #NCTN #NeuroendocrineCancer Trial: (A021901) Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors, led by Dr. @thomashopemd @ALLIANCE_org Learn more: https://t.co/yReZjDbSE7 (@NCICTEP_ClinRes)
over 2 years ago
Clinical
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
everolimus • Lutathera (lutetium Lu 177 dotatate)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login